161 related articles for article (PubMed ID: 35177256)
1. [When to consider type I interferonopathy in adulthood?].
David C; Frémond ML
Rev Med Interne; 2022 Jun; 43(6):347-355. PubMed ID: 35177256
[TBL] [Abstract][Full Text] [Related]
2. [Type I interferonopathies. Literature review].
Picard C; Belot A
Rev Med Interne; 2018 Apr; 39(4):271-278. PubMed ID: 27659742
[TBL] [Abstract][Full Text] [Related]
3. Genetic interferonopathies: An overview.
Eleftheriou D; Brogan PA
Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):441-459. PubMed ID: 29773266
[TBL] [Abstract][Full Text] [Related]
4. Toward a better understanding of type I interferonopathies: a brief summary, update and beyond.
Yu ZX; Song HM
World J Pediatr; 2020 Feb; 16(1):44-51. PubMed ID: 31377974
[TBL] [Abstract][Full Text] [Related]
5. Three Copies of Four Interferon Receptor Genes Underlie a Mild Type I Interferonopathy in Down Syndrome.
Kong XF; Worley L; Rinchai D; Bondet V; Jithesh PV; Goulet M; Nonnotte E; Rebillat AS; Conte M; Mircher C; Gürtler N; Liu L; Migaud M; Elanbari M; Habib T; Ma CS; Bustamante J; Abel L; Ravel A; Lyonnet S; Munnich A; Duffy D; Chaussabel D; Casanova JL; Tangye SG; Boisson-Dupuis S; Puel A
J Clin Immunol; 2020 Aug; 40(6):807-819. PubMed ID: 32572726
[TBL] [Abstract][Full Text] [Related]
6. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases.
de Jesus AA; Hou Y; Brooks S; Malle L; Biancotto A; Huang Y; Calvo KR; Marrero B; Moir S; Oler AJ; Deng Z; Montealegre Sanchez GA; Ahmed A; Allenspach E; Arabshahi B; Behrens E; Benseler S; Bezrodnik L; Bout-Tabaku S; Brescia AC; Brown D; Burnham JM; Caldirola MS; Carrasco R; Chan AY; Cimaz R; Dancey P; Dare J; DeGuzman M; Dimitriades V; Ferguson I; Ferguson P; Finn L; Gattorno M; Grom AA; Hanson EP; Hashkes PJ; Hedrich CM; Herzog R; Horneff G; Jerath R; Kessler E; Kim H; Kingsbury DJ; Laxer RM; Lee PY; Lee-Kirsch MA; Lewandowski L; Li S; Lilleby V; Mammadova V; Moorthy LN; Nasrullayeva G; O'Neil KM; Onel K; Ozen S; Pan N; Pillet P; Piotto DG; Punaro MG; Reiff A; Reinhardt A; Rider LG; Rivas-Chacon R; Ronis T; Rösen-Wolff A; Roth J; Ruth NM; Rygg M; Schmeling H; Schulert G; Scott C; Seminario G; Shulman A; Sivaraman V; Son MB; Stepanovskiy Y; Stringer E; Taber S; Terreri MT; Tifft C; Torgerson T; Tosi L; Van Royen-Kerkhof A; Wampler Muskardin T; Canna SW; Goldbach-Mansky R
J Clin Invest; 2020 Apr; 130(4):1669-1682. PubMed ID: 31874111
[TBL] [Abstract][Full Text] [Related]
7. [Type I interferonopathies].
Munoz J; Marque M; Dandurand M; Meunier L; Crow YJ; Bessis D
Ann Dermatol Venereol; 2015 Nov; 142(11):653-63. PubMed ID: 26363997
[TBL] [Abstract][Full Text] [Related]
8. Lung involvement in monogenic interferonopathies.
Cazzato S; Omenetti A; Ravaglia C; Poletti V
Eur Respir Rev; 2020 Dec; 29(158):. PubMed ID: 33328278
[TBL] [Abstract][Full Text] [Related]
9. Type I Interferonopathies in Childhood.
Haşlak F; Kılıç Könte E; Aslan E; Şahin S; Kasapçopur Ö
Balkan Med J; 2023 May; 40(3):165-174. PubMed ID: 37161741
[TBL] [Abstract][Full Text] [Related]
10. Assessment of type I interferon signatures in undifferentiated inflammatory diseases: A Japanese multicenter experience.
Miyamoto T; Honda Y; Izawa K; Kanazawa N; Kadowaki S; Ohnishi H; Fujimoto M; Kambe N; Kase N; Shiba T; Nakagishi Y; Akizuki S; Murakami K; Bamba M; Nishida Y; Inui A; Fujisawa T; Nishida D; Iwata N; Otsubo Y; Ishimori S; Nishikori M; Tanizawa K; Nakamura T; Ueda T; Ohwada Y; Tsuyusaki Y; Shimizu M; Ebato T; Iwao K; Kubo A; Kawai T; Matsubayashi T; Miyazaki T; Kanayama T; Nishitani-Isa M; Nihira H; Abe J; Tanaka T; Hiejima E; Okada S; Ohara O; Saito MK; Takita J; Nishikomori R; Yasumi T
Front Immunol; 2022; 13():905960. PubMed ID: 36211342
[TBL] [Abstract][Full Text] [Related]
11. Type I Interferonopathies: from a Novel Concept to Targeted Therapeutics.
Melki I; Frémond ML
Curr Rheumatol Rep; 2020 Jun; 22(7):32. PubMed ID: 32548765
[TBL] [Abstract][Full Text] [Related]
12. [Type I interferonopathies. Systemic inflammatory diseases triggered by type I interferons].
Günther C; Schmidt F; König N; Lee-Kirsch MA
Z Rheumatol; 2016 Mar; 75(2):134-40. PubMed ID: 26744186
[TBL] [Abstract][Full Text] [Related]
13. Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome.
Meuwissen ME; Schot R; Buta S; Oudesluijs G; Tinschert S; Speer SD; Li Z; van Unen L; Heijsman D; Goldmann T; Lequin MH; Kros JM; Stam W; Hermann M; Willemsen R; Brouwer RW; Van IJcken WF; Martin-Fernandez M; de Coo I; Dudink J; de Vries FA; Bertoli Avella A; Prinz M; Crow YJ; Verheijen FW; Pellegrini S; Bogunovic D; Mancini GM
J Exp Med; 2016 Jun; 213(7):1163-74. PubMed ID: 27325888
[TBL] [Abstract][Full Text] [Related]
14. Failure to thrive, interstitial lung disease, and progressive digital necrosis with onset in infancy.
Chia J; Eroglu FK; Özen S; Orhan D; Montealegre-Sanchez G; de Jesus AA; Goldbach-Mansky R; Cowen EW
J Am Acad Dermatol; 2016 Jan; 74(1):186-9. PubMed ID: 26584874
[TBL] [Abstract][Full Text] [Related]
15. Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies.
Kim H; Gunter-Rahman F; McGrath JA; Lee E; de Jesus AA; Targoff IN; Huang Y; O'Hanlon TP; Tsai WL; Gadina M; Miller FW; Goldbach-Mansky R; Rider LG
Arthritis Res Ther; 2020 Apr; 22(1):69. PubMed ID: 32252809
[TBL] [Abstract][Full Text] [Related]
16. Monogenetic causes of chilblains, panniculitis and vasculopathy: the Type I interferonopathies.
Papa R; Volpi S; Gattorno M
G Ital Dermatol Venereol; 2020 Oct; 155(5):590-598. PubMed ID: 32618445
[TBL] [Abstract][Full Text] [Related]
17. Comparison of RT-qPCR and Nanostring in the measurement of blood interferon response for the diagnosis of type I interferonopathies.
Pescarmona R; Belot A; Villard M; Besson L; Lopez J; Mosnier I; Mathieu AL; Lombard C; Garnier L; Frachette C; Walzer T; Viel S
Cytokine; 2019 Jan; 113():446-452. PubMed ID: 30413290
[TBL] [Abstract][Full Text] [Related]
18. COPA syndrome, 5 years after: Where are we?
Frémond ML; Nathan N
Joint Bone Spine; 2021 Mar; 88(2):105070. PubMed ID: 32919065
[TBL] [Abstract][Full Text] [Related]
19. Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus.
Kim H; Sanchez GA; Goldbach-Mansky R
J Mol Med (Berl); 2016 Oct; 94(10):1111-1127. PubMed ID: 27678529
[TBL] [Abstract][Full Text] [Related]
20. Aicardi-Goutières syndrome-associated mutation at ADAR1 gene locus activates innate immune response in mouse brain.
Guo X; Wiley CA; Steinman RA; Sheng Y; Ji B; Wang J; Zhang L; Wang T; Zenatai M; Billiar TR; Wang Q
J Neuroinflammation; 2021 Jul; 18(1):169. PubMed ID: 34332594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
